Across TCGA pan-cancer cohorts, VMAC mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VMAC data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher VMAC mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VMAC expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where VMAC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.721	1.000	.011	9	view →
PDAC	DFS	Median	III,IV	0.834	0.228	.024	6	view →
LSCC	DFS	Quartile	All	0.606	1.000	.022	6	view →
LUAD	OS	Quartile	All	1.000	0.626	.012	5	view →
HNSC	OS	Median	II,III,IV	0.720	0.876	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: VMAC tumor-vs-normal RNA expression · all VMAC data types